Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ESMO Immuno-Oncology 2025 | Monitoring ADC and checkpoint inhibitor-related toxicity in oncology

Laurence Buisseret, MD, PhD, Institute Jules Bordet, Brussels, Belgium, highlights the distinct toxicity profiles of immune checkpoint inhibitors and antibody-drug conjugates (ADCs), noting that while there is no overlapping toxicity due to different mechanisms, certain organs such as the lungs and skin can be affected by both, resulting in immune-related adverse events like pneumonitis and rash. Careful dose optimization, enhanced monitoring, and strategic sequencing are all needed to improve tolerability. This interview took place at 2025 European Society for Medical Oncology (ESMO) Immuno-Oncology Congress in London, UK.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

Transcript

Yeah. So there is no, so the spectrum of toxicity of immune checkpoint inhibitors is quite different than the one that is related with ADC. So it is not the same mechanism of toxicity and there is no overlapping toxicity, but there are some organs that can have immune-related toxicity and also toxicity linked to the ADC, for example, pneumonitis. So for these overlapping organs that can be touched by adverse events by both modalities, we have to be really vigilant...

Yeah. So there is no, so the spectrum of toxicity of immune checkpoint inhibitors is quite different than the one that is related with ADC. So it is not the same mechanism of toxicity and there is no overlapping toxicity, but there are some organs that can have immune-related toxicity and also toxicity linked to the ADC, for example, pneumonitis. So for these overlapping organs that can be touched by adverse events by both modalities, we have to be really vigilant. So I’m thinking of pneumonitis, but also of rash. So this, we will need some careful dose optimization and better monitoring of the disease and see with some sequencing if it can influence tolerability.

This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.

Read more...